Paper Details

  1. Home
  2. Paper Details

Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.

Author: AgustssonArnar S, BjornssonEinar S, GudmundsdottirBrynja R, HreinssonJohann P, IngasonArnar B, LundSigrun H, OnundarsonPall T, PalssonDaniel A, ReynissonIndridi E, RumbaEdward, TryggvasonGeir

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 2098 patients receiving apixaban, 474 receiving dabigatran, 3106 receiving rivaroxaban, and 1403 receiving warfarin found that warfarin treatment was associated with higher rates of clinically relevant epistaxis compared to direct oral anticoagulants.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Although epistaxis is one of the most common side effects of oral anticoagulation, it is unclear whether epistaxis rates vary between different oral anticoagulants (OAC). OBJECTIVE: To compare rates of clinically relevant epistaxis between OAC. METHODS: Epistaxis event rates were compa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/joim.13498

データ提供：米国国立医学図書館（NLM）

Warfarin and Epistaxis: A Nationwide Study

In the field of cardiovascular health, understanding the risks and benefits of different anticoagulants is crucial. This study investigates the occurrence of epistaxis, a common side effect of oral anticoagulation, across various medications. The researchers analyzed data from a nationwide population-based cohort study to compare epistaxis rates between warfarin and newer direct oral anticoagulants (DOACs).

Higher Epistaxis Risk with Warfarin

The study found a significantly higher rate of clinically relevant epistaxis in patients taking warfarin compared to those taking DOACs (apixaban, dabigatran, and rivaroxaban). These findings have significant implications for patient care and treatment decisions, suggesting that DOACs may offer a safer alternative for patients with a higher risk of epistaxis.

Clinical Implications and Patient Safety

This research highlights the importance of considering potential side effects when choosing anticoagulants. Patients and healthcare providers should be aware of the increased risk of epistaxis associated with warfarin and carefully assess the individual patient's risk factors and potential benefits.

Dr.Camel's Conclusion

The study provides valuable data for clinicians to navigate the complexities of anticoagulation therapy. It underscores the importance of considering the potential side effects of medications and choosing the most appropriate treatment for individual patients. By understanding the nuances of different anticoagulants, we can enhance patient safety and improve overall care.

Date :
  1. Date Completed 2022-08-05
  2. Date Revised 2022-10-22
Further Info :

Pubmed ID

35411982

DOI: Digital Object Identifier

10.1111/joim.13498

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.